Article,

Molecular cloning and radioligand binding characterization of the chemokine receptor \CCR5\ from rhesus macaque and human

, , , , , , and .
Biochemical Pharmacology, 71 (1–2): 163 - 172 (2005)
DOI: https://doi.org/10.1016/j.bcp.2005.10.024

Abstract

The aim of this study was to determine if macaque represents a suitable species for the pre-clinical evaluation of novel \CCR5\ antagonists, such as maraviroc (UK-427,857). To do this we cloned and expressed \CCR5\ from rhesus macaque and compared the binding properties of 125I-MIP-1β and 3H-maraviroc with human recombinant CCR5. 125I-MIP-1β bound with similar high affinity to \CCR5\ from macaque (Kd = 0.24 ± 0.05 nM) and human (Kd = 0.23 ± 0.05 nM) and with similar kinetic properties. In competition binding studies the affinity of a range of human chemokines for macaque \CCR5\ was also similar to human CCR5. Maraviroc inhibited binding of 125I-MIP-1β to \CCR5\ from macaque and human with similar potency (IC50 = 17.50 ± 1.24 nM and 7.18 ± 0.93 nM, respectively) and antagonised MIP-1β induced intracellular calcium release mediated through \CCR5\ from macaque and human with similar potency (IC50 = 17.50 ± 3.30 nM and 12.07 ± 1.89, respectively). 3H-maraviroc bound with high affinity to \CCR5\ from macaque (Kd = 1.36 ± 0.07 nM) and human (Kd = 0.86 ± 0.08 nM), but was found to dissociate ∼10-fold more quickly from macaque CCR5. However, as with the human receptor, maraviroc was shown to be a high affinity, potent functional antagonist of macaque \CCR5\ thereby indicating that the macaque should be a suitable species in which to evaluate the pharmacology, safety and potential mechanism-related toxicology of novel \CCR5\ antagonists.

Tags

Users

  • @salotz

Comments and Reviews